|
 |
|
| |
|
Newsletter Sponsor
|
|
[PCI-5-7-2026] Integrated Solutions for Ultra-High Potent OSD Products
As pipelines push into ultra-high potency, conventional HPAPI capability is no longer enough. PCI Pharma Services supports oral solid dose manufacturing at validated OEB 5–6 levels, with infrastructure, analytics, and controls designed for sub-microgram OELs. Our integrated model also includes clinical and commercial packaging to support development and manufacturing programmes, helping sponsors manage risk, reduce complexity, and progress ultra-potent assets with confidence.
 |
 |
|
|
|
|
|
|
 |
Featured Articles |
 |
|
|
 |
|
Executive Q&A - Early Drug Development
In this Q&A, we explore early-stage pharmaceutical drug development trends, key scientific and technical challenges, and the role emerging technologies play in enhancing efficiency and quality during ...
read more » |
 |
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
|
Events
|
|
|
| |
|
|
|
|
|
ChemOutsourcing 2026
Boston, Massachusetts – 09/15/2026
ChemOutsourcing 2026, now hosted in Boston on September 15–17, is the premier meeting place for drug developers seeking pharmaceutical ingredients and...
event details » |
 |
|
|
 |
|
|
|